MindWalk Files EU Patent for Biological Data Layer, Pressuring Absci
ABSI•MindWalk Holdings filed EU patent EP26187897.9 for its high-dimensional biological data structures powering its HYFT, ReefIQ and LensAI platforms, deepening proprietary advantage in AI-driven drug discovery. This move intensifies competitive pressure on Absci to bolster its own structured data capabilities as AI discovery spending nears $8 billion by 2030.
1. Patent Filing Details
On July 6, MindWalk filed European patent application No. EP26187897.9 protecting high-dimensional data structures for biological subsequences and property inference. The application seeks to secure the enriched representation architecture that underpins its HYFT®, ReefIQ™ and LensAI™ platforms, emphasizing structured, traceable biological context in drug discovery workflows.
2. Competitive Implications for Absci
By focusing on the data layer rather than model parameters alone, MindWalk aims to establish a durable advantage as frontier AI models become interchangeable. This strategic filing raises the bar for competitors like Absci, which must enhance its proprietary data architecture to maintain differentiation in the bio-native AI space.
3. AI Drug Discovery Market Growth
Spending on AI in drug discovery is projected to grow from roughly $5 billion in 2026 to over $8 billion by 2030, underpinned by more than $250 billion in annual pharmaceutical R&D. As investment surges, companies are racing to patent and protect data infrastructures that unlock efficient model reasoning and knowledge reuse.
